Intersect ENT (XENT) Stock Pops on First Trading Day After IPO

NEW YORK (TheStreet) -- Intersect ENT  (XENT) surged more than 18% Thursday, its first day of trading after its IPO.

The biotech company, which manufactures drug delivery devices used by Ear, Nose and Throat doctors, priced its initial public offering of 5 million shares at $11 a share, the low end of the expected $11 to $13 range. The offering, which the company expects to close on or around July 29, includes a 30-day option for underwriters to purchase up to an additional 750,000 shares.

The stock opened at $13.20 and hit a high of $13.65 as of 12:57 p.m., by which point more than 2.6 million shares had changed hands.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

XENT Price Chart XENT Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China